Notas de prensa

  • 16 de octubre de 2007
  • 225

Amgen Announces Webcast of 2007 Third Quarter Financial Results

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 16, 2007--Amgen (NASDAQ:AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 24, 2007 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen´s senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen´s business given by management at certain investor and medical conferences, can be found on Amgen´s Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen´s Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen

Destacadas

  • Un estudio clínico español demuestra por primera vez la eficacia de la terapia génica en pacientes con anemia de Fanconi

    Farmanews Farmanews

    Un estudio clínico español demuestra por primera vez la eficacia de la terapia génica en pacientes con anemia de Fanconi

    Leer más
  • Docentes de la Universidad Internacional de Valencia destacan la búsqueda de apoyo como elemento clave en la recuperación del bienestar tras la pérdida

    Farmanews Farmanews

    Docentes de la Universidad Internacional de Valencia destacan la búsqueda de apoyo como elemento clave en la recuperación del bienestar tras la pérdida

    Leer más
  • Los linfomas cutáneos son procesos linfoproliferativos que se manifiestan inicialmente en la piel, por lo que el papel del dermatólogo en el diagnóstico temprano es fundamental

    Alba Martín

    Los linfomas cutáneos son procesos linfoproliferativos que se manifiestan inicialmente en la piel, por lo que el papel del dermatólogo en el diagnóstico temprano es fundamental

    Leer más

Newsletter

Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.

Contacto

Avda. Mare de Déu de Lourdes, 108,
08757, Corbera de Llobregat
(Barcelona), España